NASDAQ$TNXP
Tonix Pharmaceuticals Holding Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
TNXP Q2 2024 — $150.0M revenue, 30.00 EPS
The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Tonix Pharmaceuticals Holding Corp reported Q2 2024 results. Diluted EPS came in at $30.00. Net income of $93.7M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $150.0M.
- Diluted EPS: $30.00.
- Net income: $93.7M.
- Operating income: $77K.
Headline financials
Revenue & EPS history
Tonix · Revenue · Quarterly
$2.21M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-1.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
-12.7%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+12.9%
Q1 2016
Best reaction
-31.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | +11.7% | — | |
| Q4 2025 | +0.0% | +19.1% | -2.0% | |
| Q3 2025 | -0.9% | -6.5% | +16.2% | |
| Q1 2025 | +5.2% | +45.9% | +80.0% | |
| Q4 2024 | -2.4% | +48.6% | -23.5% | |
| Q3 2024 | +0.6% | -7.1% | +64.3% | |
| Q2 2024 | -2.6% | -21.7% | -65.2% | |
| Q1 2024 | +4.8% | +17.6% | -79.6% | |
| Q4 2023 | +2.5% | -10.5% | -5.3% | |
| Q3 2023 | -4.3% | -6.1% | -18.4% | |
| Q2 2023 | +1.8% | +1.1% | -4.2% | |
| Q1 2023 | -31.7% | -40.6% | -41.2% | |
| Q4 2022 | +8.7% | -3.2% | -9.7% | |
| Q3 2022 | +1.5% | +4.4% | -17.8% | |
| Q2 2022 | -11.4% | -11.4% | -42.4% | |
| Q1 2022 | -5.4% | -7.1% | -49.3% | |
| Q4 2021 | -4.7% | +9.1% | -13.6% | |
| Q3 2021 | +7.4% | -1.8% | -18.2% | |
| Q2 2021 | +12.5% | -1.4% | -2.9% | |
| Q1 2021 | -2.8% | +0.0% | +22.6% | |
| Q4 2020 | +0.0% | +14.2% | -14.2% | |
| Q3 2020 | -1.8% | +10.7% | +16.1% | |
| Q2 2020 | -12.1% | -12.1% | -30.2% | |
| Q1 2020 | -3.3% | -2.8% | -4.2% | |
| Q4 2019 | -13.2% | -14.1% | -20.0% | |
| Q3 2019 | -3.1% | +0.8% | -59.5% | |
| Q2 2019 | +0.5% | +0.0% | +4.3% | |
| Q1 2019 | -9.5% | -18.0% | -21.0% | |
| Q4 2018 | -8.7% | -19.4% | -15.6% | |
| Q3 2018 | -10.6% | -18.5% | -54.8% | |
| Q2 2018 | -2.9% | +15.2% | -21.0% | |
| Q1 2018 | +6.2% | +11.6% | +48.6% | |
| Q4 2017 | -4.7% | -1.1% | -13.4% | |
| Q3 2017 | -7.9% | -2.2% | +3.3% | |
| Q1 2017 | +0.5% | +4.9% | +3.4% | |
| Q4 2016 | -12.5% | -10.9% | -15.0% | |
| Q3 2016 | +1.3% | -4.5% | -6.8% | |
| Q2 2016 | +9.7% | +23.7% | -58.0% | |
| Q1 2016 | +12.9% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | +1.8% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | -2.5% | — | — | |
| Q2 2014 | +12.4% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | +11.2% | — | — | |
| Q3 2013 | +0.5% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | +4.7% | — | — | |
| Q1 2012 | -12.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2009 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro